Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
View Patent ↗The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.
1. A pharmaceutical composition consisting of
(i) 150-500 mg aliskiren or a pharmaceutically acceptable salt thereof,
(ii) 1.0-40 mg amlodipine or a pharmaceutically acceptable salt thereof,
(iii) 5-200 mg hydrochlorothiazide, and one or more pharmaceutically acceptable carriers,
wherein the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered in combination achieve a greater therapeutic effect than the therapeutic effects achievable with the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered alone.
2. A pharmaceutical composition according to claim 1 , wherein the amount of amlodipine or a pharmaceutically acceptable salt thereof is from 2.5 to 25 mg.
3. A pharmaceutical composition according to claim 2 , wherein the amount of hydrochlorothiazide is from 5 to 25 mg.
4. A pharmaceutical composition according to claim 1 , wherein the amount of hydrochlorothiazide is from 5 to 25 mg.
5. A pharmaceutical composition consisting of:
(i) 150-500 mg aliskiren or a pharmaceutically acceptable salt thereof,
(ii) 1.0-40 mg amlodipine or a pharmaceutically acceptable salt thereof, and
(iii) 5-200 mg hydrochlorothiazide, and one or more pharmaceutically acceptable carriers,
wherein the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide are administered in a unit dosage form, said combination achieving a greater therapeutic effect than the therapeutic effects achievable with the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered alone.
6. A pharmaceutical composition consisting of:
(i) 140-220 mg aliskiren or a pharmaceutically acceptable salt thereof,
(ii) 2.0-12 mg amlodipine or a pharmaceutically acceptable salt thereof, and
(iii) 5-15 mg hydrochlorothiazide, and one or more pharmaceutically acceptable carriers,
wherein the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide are administered in a unit dosage form, said combination achieving a greater therapeutic effect than the therapeutic effects achievable with the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered alone.
7. A pharmaceutical composition consisting of:
(i) 550-700 mg aliskiren or a pharmaceutically acceptable salt thereof,
(ii) 2.0-12 mg amlodipine or a pharmaceutically acceptable salt thereof, and
(iii) 5-30 mg hydrochlorothiazide, and one or more pharmaceutically acceptable carriers,
wherein the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide are administered in a unit dosage form, said combination achieving a greater therapeutic effect than the therapeutic effects achievable with the amounts of (i) aliskiren or a pharmaceutically acceptable salt thereof, (ii) amlodipine or a pharmaceutically acceptable salt thereof and (iii) hydrochlorothiazide administered alone.